In the field of longevity and cellular health, NAD⁺ (nicotinamide adenine dinucleotide) has long been surrounded by both excitement and skepticism. For years, countless animal studies have promised rejuvenation miracles — yet the key questions remain:
👉 How far has NAD⁺ advanced in human clinical research?
👉 Is it truly safe and effective for humans?
Recently, a comprehensive review published in Nature Aging by Professor Evandro Fei Fang from the University of Oslo systematically summarized the current status of NAD⁺ clinical research.
We had the privilege of hosting Professor Fang at our longevity clinic last year for an in-depth lecture on NAD⁺ — a session that deeply inspired both our team and the audience. Now, an even greater opportunity is on the horizon:
🧬 On November 27, 2025, the 10th No-Age/Alzheimer’s Disease and the 3rd Norway–UK Aging and Dementia Conference will be held in Norway, co-organized by Professor Fang. XI’AN SPRINGJIA BIO-TECHNIQUE CO., LTD will also join this academic journey, participating in discussions on cutting-edge NAD⁺ science and translational medicine.
Before the conference begins, let us revisit the highlights of this landmark review — a “prelude” to what’s next in the story of NAD⁺.
🧠 Neurology
Alzheimer’s Disease (AD) / Mild Cognitive Impairment (MCI):
A Phase II randomized, double-blind, placebo-controlled study (60 participants) showed memory improvement after 84 days of NR supplementation. Another 10-week study found NR increased NAD⁺ levels and reduced epigenetic age, though cognitive outcomes remained unchanged.
Parkinson’s Disease (PD):
Clinical data suggest NR (1g/day) enhances total brain NAD⁺, reduces inflammation, and improves motor function. The NR-SAFE trial confirmed safety even at 3g/day — setting an upper boundary for future studies.
Amyotrophic Lateral Sclerosis (ALS):
Combined therapy (NR 1000 mg + pterostilbene 200 mg) showed early signs of muscle strength improvement. A 320-participant trial is expected to conclude in late 2025.
❤️ Cardiology
NMN supplementation for 30 days significantly reduced systolic and diastolic blood pressure in hypertensive patients.
While niacin (NA) demonstrated Phase III success decades ago — lowering recurrent myocardial infarction by 26% — its side effects on glucose metabolism and stroke risk have limited clinical use.
🧬 Endocrinology & Metabolism
In obese, insulin-resistant men, NR increased urinary NAD⁺ metabolites but did not improve insulin sensitivity.
However, in prediabetic postmenopausal women, NMN supplementation significantly improved muscle insulin sensitivity — suggesting sex-specific responses and metabolic individuality.
💪 Musculoskeletal & Respiratory Findings
Sarcopenia:
NA restored muscle NAD⁺ levels in mitochondrial myopathy patients but had no effect on healthy controls.
COPD:
NR doubled NAD⁺ levels and lowered inflammation in patients but showed limited benefit in healthy subjects.
⚠️ Safety and Future Perspectives
High-dose NR (up to 3g/day) has demonstrated safety in humans. Yet, as with niacin’s example, caution remains essential. The route of administration, duration, and population specificity all influence efficacy.
New technologies — such as microbial fermentation, enzymatic synthesis, and nano-carriers — are advancing the bioavailability and clinical potential of NAD⁺ precursors.
But the real breakthrough may not lie in capsules — rather in time, data, and the persistence of rational science.
🌍 About XI’AN SPRINGJIA BIO-TECHNIQUE CO., LTD
XI’AN SPRINGJIA BIO-TECHNIQUE CO., LTD is dedicated to human health and longevity, with long-term commitment to research and development of key active ingredients.
Our NAD⁺ and NMN series products are bestsellers, known for their high purity, stable quality, and have earned broad trust and recognition from both domestic and international clients.